<SEC-DOCUMENT>0001193125-17-360723.txt : 20171205
<SEC-HEADER>0001193125-17-360723.hdr.sgml : 20171205
<ACCEPTANCE-DATETIME>20171205060732
ACCESSION NUMBER:		0001193125-17-360723
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171205
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171205
DATE AS OF CHANGE:		20171205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LivaNova PLC
		CENTRAL INDEX KEY:			0001639691
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				981268150
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37599
		FILM NUMBER:		171238599

	BUSINESS ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG
		BUSINESS PHONE:		4402033250662

	MAIL ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Plc
		DATE OF NAME CHANGE:	20150420

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Ltd
		DATE OF NAME CHANGE:	20150415
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d486149d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;5, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486149g93w11.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>LivaNova PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-37599</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-1268150</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20 Eastbourne Terrace </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London, W2 6LG </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United
Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(44) 203 325 0660 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number,&nbsp;Including Area Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section&nbsp;13(a) of the Exchange Act.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><U>Item</U><U>&nbsp;</U><U>8.01</U></B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Other Events</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2017, LivaNova PLC (&#147;LivaNova&#148;) announced that it had
entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc. (&#147;ImThera&#148;), a privately-held, early-stage development company with a focus on neurostimulation for the treatment of obstructive sleep apnea.
LivaNova has been an investor in ImThera since 2011 and has agreed to pay up to approximately $225&nbsp;million to acquire the remaining outstanding interests of ImThera. <FONT STYLE="white-space:nowrap">Up-front</FONT> costs are approximately
$78&nbsp;million with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected to be near-term accretive and is expected to close in early 2018 (subject to approvals and other customary closing conditions).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of LivaNova&#146;s press release dated December&nbsp;5, 2017 announcing the acquisition is attached hereto as Exhibit 99.1 </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><U>Item</U><U>&nbsp;</U><U>9.01</U></B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>Financial Statements and Exhibits</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d486149dex991.htm">Press Release issued by LivaNova PLC dated December&nbsp;5, 2017 </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LivaNova PLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: December&nbsp;5, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Catherine Moroz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:&nbsp;&nbsp;Catherine Moroz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:&nbsp;&nbsp;&nbsp;&nbsp;Company Secretary</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d486149dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g486149g93w11.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 99.1</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B>NEWS RELEASE</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LivaNova to Acquire ImThera Medical, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company will enter Obstructive Sleep Apnea space, enhancing its portfolio of Neuromodulation treatments and therapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>London, Dec. 5, 2017 &#151;</B> LivaNova PLC (NASDAQ:LIVN) (&#147;LivaNova&#148; or the &#147;Company&#148;), a market-leading medical technology company,
today announced it has entered into an agreement to acquire the remaining outstanding interests in ImThera Medical, Inc. (&#147;ImThera&#148;). Headquartered in San Diego, Calif., ImThera is a privately held company focused on neurostimulation for
the treatment of obstructive sleep apnea (&#147;OSA&#148;). ImThera manufactures an implantable device that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The ImThera device is highly aligned with our existing Neuromodulation business, and we are extremely excited about the opportunity to optimize the
technology and fold it into our universal platform. In the near term, we will focus on expanding ImThera&#146;s current commercial presence in the European market, while advancing enrollment in a U.S. Food and Drug Administration (FDA) pivotal
trial,&#148; said Damien McDonald, LivaNova&#146;s Chief Executive Officer. &#147;The OSA market is large and growing, with many unmet needs. With our strong commercial capabilities and robust manufacturing, we look forward to bringing this
innovative technology to the large patient population that has been unsuccessful with other treatments, allowing them to improve their quality of life.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with OSA can experience impaired daytime functionality, along with severe comorbidities such as heart failure and stroke. ImThera&#146;s implantable
device received CE Mark in 2012 and is indicated for patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (&#147;CPAP&#148;) therapy. For these patients, the device is designed to reduce or
eliminate sleep apnea, as demonstrated through clinical studies and its initial commercial use in Europe. Enrollment in a pivotal study is currently under way with the FDA to obtain premarket approval for the OSA implant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Adding ImThera and its obstructive sleep apnea device to our portfolio will strengthen our position as a leader in the field of neuromodulation,&#148;
said Jason Richey, LivaNova&#146;s President of&nbsp;North America&nbsp;and General Manager of the Neuromodulation business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LivaNova has been an investor in ImThera since 2011 and has agreed to pay up to approximately $225&nbsp;million
to acquire the remaining outstanding interests of ImThera. <FONT STYLE="white-space:nowrap">Up-front</FONT> costs are approximately $78&nbsp;million with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected
to be near-term accretive and is expected to close in early 2018 (subject to approvals and other customary closing conditions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;ImThera Medical
shares LivaNova&#146;s mission to help patients live longer, better lives. We are proud of the accomplishments we have made in developing an effective CPAP alternative for individuals suffering from OSA. This acquisition will benefit healthcare
providers, shareholders and most of all, the patients who are at the heart of everything we do,&#148; said Marcelo Lima, ImThera&#146;s Founder, President and Chief Executive Officer. &#147;This is the culmination of several years of hard work by
our team of dedicated professionals. We welcome the opportunity to become part of the LivaNova family and look forward to the continued evolution of our product.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">About ImThera Medical, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ImThera Medical is a global leader
in neurostimulation for the treatment of obstructive sleep apnea. Headquartered in San Diego, ImThera was founded to improve the lives of patients suffering from the debilitating effects of OSA. ImThera&#146;s sleep therapy product is comprised of
an implanted small generator and multi-channel electrode lead, along with an external handheld remote control that can start, stop or pause therapy. ImThera collaborates with the world&#146;s top scientists and medical experts in sleep medicine, and
its product is commercially available in several countries outside the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">About LivaNova </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients
around the world. LivaNova&#146;s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than
100 countries worldwide, the company employs more than 4,500 employees. LivaNova&nbsp;operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola
(Italy),&nbsp;Houston&nbsp;(U.S.A.) and Clamart (France), respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Safe Harbor Statement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the United States Securities Act of 1933, as amended, and
Section&nbsp;21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company&#146;s future plans, strategies and
expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, &#147;may,&#148; &#147;could,&#148; &#147;seek,&#148; &#147;guidance,&#148; &#147;predict,&#148;
&#147;potential,&#148; &#147;likely,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;forecast,&#148; or variations of these terms and similar
expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but
are inherently uncertain. As a result, the Company&#146;s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and
involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company&#146;s control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements
concerning closing of the proposed acquisition of ImThera, entry into the OSA space, developing the ImThera device as an important growth platform, investing in the clinical studies, regulatory approvals, product enhancements and other steps needed
to launch this device commercially in new markets, developing ImThera as a positive addition to the Company&#146;s neuromodulation portfolio, offering patients the most advanced OSA therapy, offering a significant new therapy to patients with OSA,
adding clinical study sites for ImThera&#146;s implantable device, bringing a superior technology to market and anticipating that this transaction will meet all LivaNova long-term financial metrics and internal standards. You should carefully
consider the foregoing factors and the other risks and uncertainties that affect the Company&#146;s business, including those described in the &#147;Risk Factors&#148; section of Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT>
Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> and other documents filed
from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1)&nbsp;that LivaNova will achieve its expectations, or (2)&nbsp;concerning any result or the timing thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information in this press release is as of the date of its release. The Company does not undertake or assume
any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements,
except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to
place undue reliance on any forward-looking statements, which are made only as of the date of this press release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For more information, please visit
<U>www.livanova.com.</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LivaNova PLC Investor Relations and Media </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Karen King, </B>+1 (281) <FONT STYLE="white-space:nowrap">228-7262</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deanna Wilke,</B> +1 (281) <FONT STYLE="white-space:nowrap">727-2764</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate External Communications Manager </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Corporate.Communications@LivaNova.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">###
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g486149g93w11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486149g93w11.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MB1222W=L]A7W7^V3\ X=:_X)5:9I>CQF^UKX9Z;;W6GR*GSS6]O (;I?^!1
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%/O\ _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
